Oct 15 (Reuters) - Dug developer Transition Therapeutics Inc
TTH.TO said detailed data analysis of a study of its
experimental drug showed it would benefit a group of Alzheimer's
patients.
The company said on Thursday its drug was significantly
effective in treating patients with severe agitation and
aggression. urn:newsml:reuters.com:*:nPnchlTY